Trial of malaria drug paused
For months, President Donald Trump has promoted hydroxychloroquine as a potential treatment for COVID-19, calling the anti-malarial drug a “game changer,” asking patients, “What do you have to lose?” — and even announcing that he was taking the drug himself in an attempt to ward off the novel coronavirus.
On Monday, however, the World Health Organization announced it had temporarily halted its global trial of the drug, citing a new study that found a significantly higher risk of death among those taking hydroxychloroquine or the closely related drug chloroquine.
“The Executive Group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board,” Tedros Adhanom Ghebreyesus, the WHO’s director general, said in a briefing.
Trump, meanwhile, said Sunday he is no longer taking hydroxychloroquine, but again defended the drug as a COVID-19 treatment, pointing to “tremendous, rave reviews.”
“I believe in it enough that I took a program because I had two people in the White House that tested positive,” Trump told Sharyl Attkisson of the Sinclair Broadcast Group, noting that his “two-week course” of the drug had recently finished.
“And by the way, I’m still here,” Trump added. “To the best of my knowledge, here I am.”
The WHO’s decision is the latest setback for backers of hydroxychloroquine, which has produced a series of disappointing results in scientific studies. In April, the Food and Drug Administration warned against using the drug outside of hospitals and clinical trials over reports of “serious heart rhythm problems” linked to the drug’s use.
On Friday, the medical journal Lancet published a study of 96,000 hospitalized COVID-19 patients worldwide that found a 45 percent increased risk of death and a 411 percent increased risk of serious heart arrhythmias among those taking a cocktail of antibiotics and theantimalarial drug.
“If there was ever hope for this drug, this is the death of it,” Eric Topol, a cardiologist and director of the Scripps Research Translational Institute, told the Washington Post.
The WHO started a clinical trial earlier this year to test hydroxychloroquine along with three other experimental treatments. Due to the alarming findings published in the Lancet, Ghebreyesus said Monday, the use of hydoxychloroquine in the trial, which now has more than 3,500 patients in 17 countries, will temporarily halt.
The trial will continue for the other three drugs, and the WHO will likely decide within the next two weeks whether to resume using hydroxychloroquine, chief scientist Soumya Swaminathan told NPR.